CN100352506C - 抗惊厥剂衍生物和抗偏头痛药物联合的制药用途 - Google Patents

抗惊厥剂衍生物和抗偏头痛药物联合的制药用途 Download PDF

Info

Publication number
CN100352506C
CN100352506C CNB038091135A CN03809113A CN100352506C CN 100352506 C CN100352506 C CN 100352506C CN B038091135 A CNB038091135 A CN B038091135A CN 03809113 A CN03809113 A CN 03809113A CN 100352506 C CN100352506 C CN 100352506C
Authority
CN
China
Prior art keywords
migraine
period
dose
day
topiramate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB038091135A
Other languages
English (en)
Chinese (zh)
Other versions
CN1646168A (zh
Inventor
I·R·利文斯通
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
3 Dimensional Pharmaceuticals Inc
Original Assignee
3 Dimensional Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 3 Dimensional Pharmaceuticals Inc filed Critical 3 Dimensional Pharmaceuticals Inc
Publication of CN1646168A publication Critical patent/CN1646168A/zh
Application granted granted Critical
Publication of CN100352506C publication Critical patent/CN100352506C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNB038091135A 2002-02-26 2003-02-25 抗惊厥剂衍生物和抗偏头痛药物联合的制药用途 Expired - Lifetime CN100352506C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35989402P 2002-02-26 2002-02-26
US60/359,894 2002-02-26

Publications (2)

Publication Number Publication Date
CN1646168A CN1646168A (zh) 2005-07-27
CN100352506C true CN100352506C (zh) 2007-12-05

Family

ID=27663315

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB038091135A Expired - Lifetime CN100352506C (zh) 2002-02-26 2003-02-25 抗惊厥剂衍生物和抗偏头痛药物联合的制药用途

Country Status (18)

Country Link
US (2) US20030225002A1 (https=)
EP (1) EP1478400A1 (https=)
JP (1) JP2005518439A (https=)
KR (1) KR101008326B1 (https=)
CN (1) CN100352506C (https=)
AU (1) AU2003213242A1 (https=)
BR (1) BR0307951A (https=)
CA (1) CA2419989A1 (https=)
HR (1) HRP20040846A2 (https=)
IL (2) IL163720A0 (https=)
MX (1) MXPA04008259A (https=)
NO (1) NO20043984L (https=)
NZ (1) NZ534874A (https=)
PL (1) PL372393A1 (https=)
RU (1) RU2004126093A (https=)
UA (1) UA81110C2 (https=)
WO (1) WO2003072138A1 (https=)
ZA (1) ZA200407729B (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10334188B4 (de) * 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
DE10334187A1 (de) * 2003-07-26 2005-03-03 Schwarz Pharma Ag Substituierte 2-Aminotetraline zur Behandlung von Depressionen
WO2005079787A1 (en) * 2004-02-17 2005-09-01 Sepracor Inc. Treatment or prophylaxis of migraine or headache disorders using citalopram, escitalopram or citalopram metabolites
US20060233892A1 (en) * 2005-04-19 2006-10-19 Curt Hendrix Topiramate compositions for treatment of headache
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
FR2890564B1 (fr) * 2005-09-09 2007-10-19 Servier Lab Nouvelle association entre l'agomelatine et un inhibiteur de la recapture de la noradrenaline et les compositions pharmaceutiques qui la contiennent
CN101472644B (zh) * 2006-04-13 2014-04-23 纽帕特公司 递送抗偏头痛化合物的透皮方法和系统
WO2007127207A2 (en) * 2006-04-25 2007-11-08 Proethic Pharmaceuticals, Inc. Fixed combination dosage forms for the treatment of migraine
WO2008027557A2 (en) 2006-08-31 2008-03-06 Spherics, Inc. Topiramate compositions and methods of enhancing its bioavailability
EP2124556B1 (en) 2006-10-09 2014-09-03 Charleston Laboratories, Inc. Pharmaceutical compositions
ES2555066T3 (es) 2006-11-17 2015-12-28 Supernus Pharmaceuticals, Inc. Formulaciones de liberación sostenida de topiramato
ES2645719T3 (es) * 2006-12-04 2017-12-07 Supernus Pharmaceuticals, Inc. Formulaciones de topiramato de liberación inmediata mejoradas
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
ES2620672T3 (es) 2008-01-09 2017-06-29 Charleston Laboratories, Inc. Comprimidos de doble capa que comprenden oxicodona y prometazina
EP2331100B1 (en) * 2008-09-17 2014-07-16 The McLean Hospital Corporation Methods and kits for treating cluster headache disorders
WO2011006012A1 (en) 2009-07-08 2011-01-13 Charleston Laboratories Inc. Pharmaceutical compositions
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
JP2019507181A (ja) 2016-03-04 2019-03-14 チャールストン ラボラトリーズ，インコーポレイテッド 医薬組成物
CA3039169A1 (en) * 2016-10-06 2018-04-12 Baylor College Of Medicine Photochromatic modulation with fluorescein for the treatment of photo-oculodynia and blepharospasm
JP7476229B2 (ja) * 2019-04-15 2024-04-30 フェリン・ファーマシューティカルズ・インコーポレイテッド 片頭痛の治療

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998380A (en) * 1995-10-13 1999-12-07 New England Medical Center Hospitals, Inc. Treatment of migraine

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4513006A (en) * 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
IL103172A (en) * 1991-09-19 1997-01-10 Mcneilab Inc Preparation of chlorosulfate and sulfamate derivatives of 2, 3:4, 5-bis-o-(1-methylethylidene)-beta-d-fructopyranose and (1-methylcyclohexyl) methanol
US5242942A (en) * 1992-04-28 1993-09-07 Mcneilab, Inc. Anticonvulsant fructopyranose cyclic sulfites and sulfates
US5384327A (en) * 1992-12-22 1995-01-24 Mcneilab, Inc. Anticonvulsant sorbopyranose sulfamates
CA2264182A1 (en) * 1996-08-23 1998-02-26 Algos Pharmaceutical Corporation Anticonvulsant containing composition for treating neuropathic pain
US5891885A (en) * 1996-10-09 1999-04-06 Algos Pharmaceutical Corporation Method for treating migraine
US20020015713A1 (en) * 1996-10-24 2002-02-07 Murdock Robert W. Methods and transdermal compositions for pain relief
AU1930897A (en) * 1997-03-03 1998-09-22 Laboratoires Remilea Plant extract compositions, method of preparation, and pharmaceutical comp ositions containing them
US5855907A (en) * 1997-03-24 1999-01-05 Peyman; Gholam A. Method of treatment of migraine
US5935933A (en) * 1997-07-16 1999-08-10 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating neuropathic pain
US5760007A (en) * 1997-07-16 1998-06-02 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating neuropathic pain
GB9720270D0 (en) * 1997-09-25 1997-11-26 Pharmagene Lab Limited Medicaments for the treatment of migraine
US6068999A (en) * 1998-06-25 2000-05-30 Hendrix; Curt Dietary supplement for supporting cerebrovascular tone and treating migraine headaches
ES2228465T3 (es) * 1999-01-19 2005-04-16 Ortho-Mcneil Pharmaceutical, Inc. Uso derivados anticonvulsionantes para el tratamiento de cefaleas en brotes.
HUP0203198A3 (en) * 1999-08-20 2005-07-28 Ortho Mcneil Pharm Inc Pharmaceutical composition comprising a tramadol material and an anticonvulsant drug, process for its preparation and its use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998380A (en) * 1995-10-13 1999-12-07 New England Medical Center Hospitals, Inc. Treatment of migraine

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
偏头痛的药物治疗进展 刘岳飞等.临床荟萃，第13卷第5期 1998 *
偏头痛药物治疗近况 刘文魁.脑与神经疾病杂志，第2卷第2期 1994 *
曲坦类抗偏头痛药物的研究进展 王好山.国外医学药学分册，第27卷第3期 2000 *

Also Published As

Publication number Publication date
AU2003213242A1 (en) 2003-09-09
IL163720A (en) 2012-06-28
JP2005518439A (ja) 2005-06-23
KR101008326B1 (ko) 2011-01-13
KR20040091074A (ko) 2004-10-27
HRP20040846A2 (en) 2005-06-30
CN1646168A (zh) 2005-07-27
US20030225002A1 (en) 2003-12-04
WO2003072138A1 (en) 2003-09-04
RU2004126093A (ru) 2005-04-10
NO20043984L (no) 2004-09-23
PL372393A1 (en) 2005-07-25
BR0307951A (pt) 2004-12-21
IL163720A0 (en) 2005-12-18
NZ534874A (en) 2007-03-30
EP1478400A1 (en) 2004-11-24
ZA200407729B (en) 2006-06-28
UA81110C2 (en) 2007-12-10
CA2419989A1 (en) 2003-08-05
US20070099849A1 (en) 2007-05-03
HK1080731A1 (en) 2006-05-04
MXPA04008259A (es) 2005-05-27

Similar Documents

Publication Publication Date Title
CN100352506C (zh) 抗惊厥剂衍生物和抗偏头痛药物联合的制药用途
CA2993665C (en) Methods of treating lennox-gastaut syndrome using fenfluramine
JP2004505043A (ja) うつ病の治療で用いるに有用な抗痙攣性誘導体
US20030109546A1 (en) Treatment of psychotic disorders comprising co-therapy with anticonvulsant derivatives and atypical antipsychotics
US10576045B2 (en) Low dosage combinations of fluoxetine and reboxetine for treating obesity
KR20220101610A (ko) 펜플루라민을 사용하여 간질 환자를 치료하는 방법
WO2019136224A1 (en) Amphetamine-guanfacine combinations for treatment of neuropsychiatric disorders
HK1080731B (en) Use of a combination of anticonvulsant derivatives and anti-migraine agents in manufacture of medicaments
HK40113588A (en) Methods of treating lennox-gastaut syndrome using fenfluramine
WO2024102718A1 (en) Compositions and methods for treating insomnia
Scahill Alpha-2 adrenergic agonists in attention deficit hyperactivity disorder
HK1255881A1 (zh) 使用芬氟拉明治疗lennox-gastaut综合征的方法
HK1098358A (en) Memantine for the prevention or reduction of suicidality and for treatment of major depression associated with suicidality
AU2002307542A1 (en) Treatment of psychotic disorders comprising co-therapy with anticonvulsant derivatives and atypical antipsychotics

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1080731

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1080731

Country of ref document: HK

CX01 Expiry of patent term

Granted publication date: 20071205

CX01 Expiry of patent term